Tim is Executive Partner at Abingworth LLP, a leading global life sciences venture investment firm, which has recently become part of Carlyle (NASDAQ: CG). Tim joined Abingworth in 2005 having been Chief Executive of Abingworth’s portfolio company, Astex Therapeutics, and was instrumental in establishing it as one of the leading UK biotechnology companies which was acquired by Otsuka Pharmaceuticals and has had 3 important medicines approved by FDA. Tim has held a number of senior management positions in the US and Europe, including CEO of both Datascope Corp. and Thackray Inc, and General Manager at Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD. He is a former Director of the BIA and sat on the BVCA Venture Committee and the Wellcome Trust / NHS Health Innovation Challenge Fund. During his time at Abingworth Tim has taken board roles in a number of companies including Adaptate Biotherapeutics, Astex, Avillion, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Scorpion Therapeutics, Sientra and Venatorx.
December 3rd & 4th, 2024
December 11th& 12th 2024